SCHEMBL21484599

SCHEMBL21484599

Cc1ccc(-c2sc(NC(=O)CC#N)nc2-c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.58
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
MAPT P10636 1/20 0.54
XIAP P98170 3/20 0.53
RORC P51449 1/20 0.53
EGFR P00533 1/20 0.53
PTGS2 P35354 1/20 0.51
ACHE P22303 1/20 0.49
ADORA2A P29274 5/20 0.49
ADORA1 P30542 5/20 0.49
ADORA3 P0DMS8 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KDM4E B2RXH2 2/20 0.48
LMNA P02545 2/20 0.48
HPGD P15428 1/20 0.48
MRE11 P49959 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484729 0.93 PTGS2 (0.58) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL21484846 0.84 ALDH1A1 (0.67) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL21505993 0.80 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AMAPTRORC
SCHEMBL2753294 0.80 ADORA3 (0.74) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL21484782 0.80 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1MEN1KMT2AADORA2A
SCHEMBL21484898 0.80 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AMAPTRORC
SCHEMBL2752593 0.79 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL2753574 0.79 RORC (0.65) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL21484796 0.78 ADORA2A (0.55) SMN1; SMN2ALDH1A1MEN1KMT2AXIAP
SCHEMBL235268 0.78 ADORA3 (0.76) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 SMN1; SMN2 71/4885ALDH1A1 1635/4885MEN1 1573/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 SMN1; SMN2 71/4885ALDH1A1 1635/4885MEN1 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.